Why is Mankind Pharma falling/rising?

As of 25-Jul, Mankind Pharma Ltd's stock price is currently at 2,592.10, reflecting a slight increase of 2.1 points or 0.08%. The stock has shown a trend reversal, gaining after two consecutive days of decline. Despite a recent drop in delivery volume by 10.21% against the 5-day average, the stock remains liquid enough for trading. Over the past month, Mankind Pharma has outperformed the benchmark with a return of 12.16%, while the stock has generated a notable 21.17% return over the past year, significantly surpassing the BSE500's negative return of -0.19%. The company's high management efficiency, indicated by a return on equity (ROE) of 17.22%, and a low debt to EBITDA ratio of 0.69 times, further support its positive outlook.
In the broader market context, Mankind Pharma's recent performance contrasts with the Sensex, which has seen a slight decline of 0.36% over the past week. While the stock has experienced a year-to-date decline of 9.90%, its strong institutional holdings at 24.58% suggest confidence from investors who are typically more adept at analyzing company fundamentals. This institutional backing, combined with healthy long-term growth in operating profit at an annual rate of 23.44%, indicates that the stock is well-positioned despite short-term fluctuations. Overall, the stock's resilience in generating returns above the market average highlights its potential for recovery and growth.